InflaRx (IFRX) EBITDA Margin (2023 - 2025)
InflaRx's (IFRX) quarterly EBITDA Margin came in at 62351941390.13% in Q4 2025, down 1081377500300419.0% year-on-year from N/an in Q4 2024, and up 507962945.24% quarter-over-quarter from 12274.9% in Q3 2025.
InflaRx (IFRX) EBITDA Margin (2023 - 2025) Analysis & Trends
InflaRx has disclosed EBITDA Margin across 3 years of filings, most recently posting 62351941390.13% for Q4 2025.
- EBITDA Margin for Q4 2025 came in at 62351941390.13%, down 1081377500300419.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 46978998030.86% (down 1989608303781.0% YoY), and the FY2025 annual result was 156499645426.34%, down 12874988036352.0% from the prior year.
- EBITDA Margin came in at 62351941390.13% for Q4 2025 at InflaRx, up from 12274.9% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 10876126944394.33% in Q4 2024 to a low of 1860998132943.39% in Q4 2023.
- The 3-year median for EBITDA Margin is 12274.9% (2025), against an average of 1008608992251.02%.
- Across the five-year window, EBITDA Margin jumped 2000000000 bps in 2024 and sank 2000000000 bps in 2025, its largest moves.
- InflaRx's EBITDA Margin stood at 1860998132943.39% in 2023, then soared by 684 bps to 10876126944394.33% in 2024, then tumbled by 99 bps to 62351941390.13% in 2025.
- The last three EBITDA Margin figures came in at 62351941390.13% (Q4 2025), 12274.9% (Q3 2025), and 36847.93% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62,351,941,390.13% |
| Sep 30, 2025 | -12,274.90% |
| Jun 30, 2025 | 36,847.93% |
| Mar 31, 2025 | -23,488.90% |
| Dec 31, 2024 | 10,876,126,944,394.33% |
| Sep 30, 2024 | -14,153.78% |
| Jun 30, 2024 | 217,356.72% |
| Mar 31, 2024 | -26,868.98% |
| Dec 31, 2023 | -1,860,998,132,943.39% |